Abstract Library

#2271 Effects of Multi-Receptor Targeting Drugs in Neuroendocrine Tumors Using 3D Cell Culture

Introduction: Symptom control in functioning neuroendocrine tumors(NETs) may be difficult in some cases, thus, new therapeutic options, including multi-receptor targeting drugs are required.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Herrera-Martínez A

Authors: Herrera-Martínez A, Van Dungen R, Van Koetsveld P, Dogan-Oruc F, Culler M,

Keywords: NETs, somatostatin receptors, dopamine receptors, multi-receptor targeting drugs, hormone secretion,

#1714 CALM-NET, A Multicentre, Exploratory Study to Assess the Clinical Value of Circulating Tumour Cells (CTCs) Enumeration in Patients (Pts) with Functioning Midgut NETs Receiving Lanreotide Autogel (LAN)

Introduction: The presence of CTCs confers adverse prognosis in metastatic NET pts with heterogenous treatment history. Post treatment CTC count correlates with disease progression and overall survival.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Meyer T

Authors: Meyer T, Higgs K, Hickling M, Houchard A,

Keywords: midgut neuroendocrine tumor, CTC, lanreotide,

#1195 Neuroendocrine Gene Transcript Analysis of Blood Identifies Stable or Progressive NET Disease Treated with Somatostatin Analogs.

Introduction: An issue in NET management is defining stable or progressive disease and effective treatment. An alternative to RECIST criteria is a sensitive, reproducible blood biomarker test. Somatostatin analogs (SSA) are a chief therapy but efficacy is subjective and based on symptom control and imaging.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Alaimo D, Callahan S, Lepensky C, Jonzzon S, Teixeira N,

Keywords: Biomarker, SSA,

#1178 Treatment Satisfaction, Symptom Control and Quality of Life (QoL) with Lanreotide Autogel (LAN) in NET Patients with Carcinoid Syndrome (CS): Results from the SYMNET Study

Introduction: CS associated with NETs can have a negative impact on patients’ QoL.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Ruszniewski P, Caplin M, Valle J, Lombard-Bohas C, Poston G,

Keywords: quality of life,

#1175 Population Pharmacokinetic (PK) Analysis of Lanreotide Autogel (LAN) in the Treatment of Patients (pts) with NETs: Pooled Analysis of Four Clinical Trials

Introduction: LAN provide antitumor effects and symptom control in NET pts.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Buil-Bruna N, Jesús Garrido M, Dehez M, Manon A, Nguyen T,

Keywords: PK, dosing,